Oral corticosteroid (OCS)-sparing effect of tralokinumab in severe, uncontrolled asthma: the TROPOS study

W. Busse (Madison, United States of America), G. Brusselle (Ghent, Belgium), S. Korn (Mainz, Germany), P. Kuna (Lodz, Poland), A. Magnan (Nantes, France), D. Cohen (Gaithersburg, United States of America), K. Bowen (Gaithersburg, United States of America), T. Piechowiak (Mississauga, Canada), M. Wang (Cambridge, United Kingdom), G. Colice (Gaithersburg, United States of America)

Source: International Congress 2018 – Innovative therapies in asthma and COPD
Session: Innovative therapies in asthma and COPD
Session type: Poster Discussion
Number: 602
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Busse (Madison, United States of America), G. Brusselle (Ghent, Belgium), S. Korn (Mainz, Germany), P. Kuna (Lodz, Poland), A. Magnan (Nantes, France), D. Cohen (Gaithersburg, United States of America), K. Bowen (Gaithersburg, United States of America), T. Piechowiak (Mississauga, Canada), M. Wang (Cambridge, United Kingdom), G. Colice (Gaithersburg, United States of America). Oral corticosteroid (OCS)-sparing effect of tralokinumab in severe, uncontrolled asthma: the TROPOS study. 602

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: